APA

Luo X. D., Chen X. F., Zhou Y. & Chen X. P. (20180608). Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. : Journal of viral hepatitis.

Chicago

Luo X D, Chen X F, Zhou Y and Chen X P. 20180608. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. : Journal of viral hepatitis.

Harvard

Luo X. D., Chen X. F., Zhou Y. and Chen X. P. (20180608). Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. : Journal of viral hepatitis.

MLA

Luo X D, Chen X F, Zhou Y and Chen X P. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial. : Journal of viral hepatitis. 20180608.